Open AccessIVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY
Author(s) -
Naveen Kishoria,
Shuchi Mathur,
Veeram Parmar,
Rimple Jeet Kaur,
Harish Agarwal,
B.S Parihar,
Somil Verma
Publication year - 2020
Publication title -
paripex indian journal of research
Language(s) - English
DOI - 10.36106/paripex/4801859
Subject(s) - pneumonia , coronavirus , medicine , covid-19 , etiology , disease , ivermectin , atypical pneumonia , virology , outbreak , infectious disease (medical specialty) , veterinary medicine
A cluster of pneumonia cases of unknown etiology was reported from the city of Wuhan, in the Hubei province of China, in December 2019. A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of the disease which was subsequently termed as the coronavirus disease (COVID-19) by the World Health Organization (WHO). SARS-CoV-2 mainly affects the lower res-piratory tract and manifests as pneumonia in humans.